Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen Inc. (AMGN) vs. Biogen Inc. (BIIB) Stock Comparison
Key Takeaways
- AMGN maintains a significantly larger market capitalization of approximately $183 billion compared to BIIB's $27 billion, reflecting greater scale and stability.
- BIIB has outperformed with a one-year return of about 54%, surpassing AMGN's 24% gain, driven by pipeline momentum.
- Both stocks show similar year-to-date gains around 4%, with low betas indicating reduced volatility (AMGN 0.47, BIIB 0.16).
- Recent analyst upgrades, including UBS to Buy on BIIB, highlight its upcoming catalysts, while AMGN eyes earnings beat streak.
- AMGN reports higher profit margins (21%) and ROE (106%), underscoring operational efficiency.
Introduction
Amgen Inc. (AMGN) and Biogen Inc. (BIIB) represent prominent players in the biotechnology sector, focusing on innovative therapies for chronic diseases. This comparison is particularly relevant for healthcare sector investors and traders navigating volatile markets, seeking insights into relative performance, pipeline developments, and sentiment shifts. With both companies approaching first-quarter earnings amid broader sector rotation, understanding their business models, recent momentum, and risk profiles aids in evaluating growth potential versus stability in the current environment.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) is a leading biotechnology firm with a diversified portfolio spanning oncology, cardiovascular, bone health, and inflammation treatments, including blockbusters like Enbrel and Prolia. In recent market activity, shares have traded around $340, reflecting year-to-date gains of about 4.5% and resilience amid sector pressures. The stock's performance has been supported by strong fourth-quarter 2025 results, with revenues up 10% to $36.8 billion annually, driven by volume growth and pipeline advancements like the Dark Blue Therapeutics acquisition bolstering oncology. Sentiment remains steady with a Zacks Rank #3 (Hold) and upcoming Q1 earnings expectations of $8.49 billion in sales, though regulatory scrutiny on Tavneos has introduced some caution. Low beta (0.47) underscores defensive positioning.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) specializes in therapies for neurological and neurodegenerative diseases, with key products in multiple sclerosis (MS) like Vumerity and emerging Alzheimer's treatment Leqembi. Recent weeks have seen shares around $183, with year-to-date returns near 4% but a robust one-year gain of 54%, signaling a rebound from prior MS franchise challenges. Fourth-quarter 2025 earnings beat estimates, with EPS of $1.99 and revenues of $2.28 billion, alongside upbeat 2026 guidance; new deals like felzartamab for China enhance pipeline prospects. Analyst upgrades, such as UBS to Buy with $225 target, have lifted sentiment ahead of Q1 results, despite expected revenue dip. Low beta (0.16) highlights stability.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of over 25 top-performing AI trading bots from its library of 351 total bots that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots are dynamically selected as the most suitable for prevailing volatility, trends, and opportunities, featuring metrics like win rates often above 70%, profit factors exceeding 1.5, and backtested annualized returns ranging from 50% to over 200% depending on the model. Whether short-term scalpers, swing traders, or long-term trend followers, they offer transparency via detailed performance stats, drawdowns, and trade logs. Traders can explore and deploy these vetted options to enhance strategies amid biotech sector flux—visit the page for real-time insights.
Head-to-Head Comparison
Business models differ markedly: AMGN's broad diversification across therapeutic areas provides revenue stability, contrasting BIIB's neuro-focused specialization with higher growth potential but patent risks. Growth drivers include AMGN's consistent volume expansion and biosimilars, versus BIIB's pipeline catalysts like felzartamab and lupus data. Recent momentum favors BIIB with superior one-year returns and upgrades, while AMGN offers steadier recent weeks. Risk factors encompass regulatory hurdles for both—AMGN on Tavneos, BIIB on MS declines—within shared biotech sector exposure. Market sentiment tilts toward BIIB's rebound narrative over AMGN's maturity.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BIIB based on stronger relative one-year momentum, recent analyst upgrades, and pipeline catalysts positioning it for potential outperformance amid healthcare rotation, though AMGN's scale and earnings consistency warrant monitoring post-Q1 results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileBIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 4 bearish.
- BIIB’s TA Score: 3 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а -1.66% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +0.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.19%. For the same industry, the average monthly price growth was +6.66%, and the average quarterly price growth was +2.82%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
BIIB is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+3.19% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BIIB | AMGN / BIIB | |
| Capitalization | 186B | 29.5B | 631% |
| EBITDA | 16.7B | 2.7B | 619% |
| Gain YTD | 6.850 | 13.478 | 51% |
| P/E Ratio | 23.99 | 21.47 | 112% |
| Revenue | 37.2B | 9.94B | 374% |
| Total Cash | 12B | 4.28B | 280% |
| Total Debt | 57.3B | 6.56B | 873% |
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 26 | 100 | |
SMR RATING 1..100 | 12 | 79 | |
PRICE GROWTH RATING 1..100 | 52 | 24 | |
P/E GROWTH RATING 1..100 | 55 | 13 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (8) in the Biotechnology industry is significantly better than the same rating for BIIB (80). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (26) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for BIIB (79). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (24) in the Biotechnology industry is in the same range as AMGN (52). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for AMGN (55). This means that BIIB’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 51% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 49% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 52% | 2 days ago 54% |
| TrendWeek ODDS (%) | 2 days ago 54% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 59% |
| Advances ODDS (%) | 12 days ago 56% | 12 days ago 57% |
| Declines ODDS (%) | 6 days ago 52% | 8 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 43% | N/A |
| Aroon ODDS (%) | 2 days ago 52% | 2 days ago 68% |
Advertisement